Trump to sign executive order on psychedelic drug used abroad to treat PTSD

TL;DR

The White House is drafting an executive order to signal the Trump administration's willingness to support U.S. research into ibogaine.
Ibogaine, a naturally occurring compound from Africa, is used to treat depression, anxiety, addiction, PTSD, and brain trauma in countries where it is legal.
The executive order aims to facilitate federal funding for research on ibogaine's effectiveness, especially for veterans with PTSD and traumatic brain injuries.
Ibogaine will remain a Schedule I drug in the U.S., meaning it is illegal and has a high potential for abuse with no currently accepted medical use.
While research is in its early phases, the administration wants to determine if ibogaine is a legitimate treatment or 'snake oil'.
Serious risks associated with ibogaine include dangerous heart rhythm disturbances, which can be fatal, and at least 27 deaths have been linked to its use.
A small study suggested ibogaine paired with intravenous magnesium might safely reduce PTSD, anxiety, and depression in veterans, but more evidence is needed.
Clinics abroad where Americans seek ibogaine treatment lack U.S. regulatory oversight, with no standardized screening, monitoring, or adverse event reporting.

Continue reading the original article